31 results about "Serum GGTP" patented technology

The bacillus subtilis NX-2, or CGMCC NO.0833 is one bacillus spawn obtained through screening and is used for the production of gamma-polyglutamic acid and its salt as well as glutathione and its precursor. In optimized condition, gamma-polyglutamic acid may be accumulated to 30-50 g / L and produced in the production efficinecy of 0.8-2.5 g / L. When bacillus subtilis NX-2 is used in fermenting to produce gamma-glutamyl transpeptidase in optimized condition, the fermented liquid may reach enzyme activity of 1-5 U / ml; and the fermented liquid or separation obtained enzyme or the immobilized enzyme is used in the production of glutathione and its precursor with substrate dipeptide or dipeptide precursor converting rate of 30-80% being reached.

The present invention enhances the effects of antitumor agents and increases the sensitivity of therapy-resistant tumor cells to antitumor agents such as chemotherapeutic agents and radiation. The present invention is thus directed to compositions and methods for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals. The GGT inhibitor compounds used in the methods of the present invention comprise a class of benzylthiadiazol benzenesulfoniamides represented by the general structure Formula (I) (FIG. 1), or a pharmaceutically acceptable salt thereof, wherein any one or more of R1-R10 may be H, Cl, F, Br, I, OH, an alkoxy, or NO2. Other R groups include carrier groups linked by C,N, or O. The present invention also provides a method for the prophylaxis or treatment of a reversible airways obstruction in a mammal, such as a human, comprising administration of a therapeutically effective amount of a GGT inhibitor described herein for the prophylaxis or treatment of a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, and inner ear conditions or diseases.

The invention discloses to further optimization of a process for generating L-theanine from L-glutamine and ethylamine catalyzed by gamma-glutamyl transpeptidase secreted from recombinant pMA5-ggt / Bacillus. subtilis by using a method that double substrates are added in different batches, and belongs to the field of fermentation engineering and enzyme engineering. The process comprises the following steps: culturing the strain of bacillus subtilis which is established in previous operation and is used for secreting gamma-glutamyl transpeptidase in a fermentation tank; concentrating supernate crude enzyme liquid for conversion of theanine; on the basis, adding the substrates in different batches so as to further regulate and control the conversion process, that is, in a reaction system with 60U / mL of the enzyme liquid, adding substrates glutamine and ethylamine into the system every other two hours, wherein the addition amount of glutamine is fixed to be 20 mM, the ratio of a donor to a receptor is controlled to be 1:12, the pH value is adjusted to be 10, 164.2 mM of theanine can be obtained after 18 hours, and the conversion rate of glutamine can be up to 91.2%. The method has the advantages that the operation is simple, the cost is low, the yield of theanine is high, the substrate conversion rate is high, and the like, and is beneficial for industrial large-scale production.

The bacillus subtilis NX-2, or CGMCC NO.0833 is one bacillus spawn obtained through screening and is used for the production of gamma-polyglutamic acid and its salt as well as glutathione and its precursor. In optimized condition, gamma-polyglutamic acid may be accumulated to 30-50 g / L and produced in the production efficinecy of 0.8-2.5 g / L. When bacillus subtilis NX-2 is used in fermenting to produce gamma-glutamyl transpeptidase in optimized condition, the fermented liquid may reach enzyme activity of 1-5 U / ml; and the fermented liquid or separation obtained enzyme or the immobilized enzyme is used in the production of glutathione and its precursor with substrate dipeptide or dipeptide precursor converting rate of 30-80% being reached.

Compositions and methods for inhibiting human gamma-glutamyl transpeptidase (GGT) in vivo or in vitro and for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals, or sensitizing tumor to other therapies including radiation therapy. The GGT inhibitor compounds comprise a class of benzylthiadiazol benzenesulfoniamides. The compounds may also be used to treat a reversible airways obstruction in a mammal or a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, cardiovascular disease and inner ear conditions or diseases.

Compositions and methods for inhibiting human gamma-glutamyl transpeptidase (GGT) in vivo or in vitro and for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals, or sensitizing tumor to other therapies including radiation therapy. The GGT inhibitor compounds comprise a class of benzylthiadiazol benzenesulfoniamides. The compounds may also be used to treat a reversible airways obstruction in a mammal or a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, cardiovascular disease and inner ear conditions or diseases.

The invention discloses a Liuwei Anxiao pharmaceutical composition and application of a preparation thereof in preparation of a drug for treating alcoholic hepatitis. The Liuwei Anxiao pharmaceutical composition comprises six medicine ingredients, namely, Tibet inula root, rheum officinale, rhizoma kaempferiae, fumed gypsum, fructus chebulae and tronae. The clinical test shows that the Liuwei Anxiao pharmaceutical composition can protect alcoholic liver injury and can also obviously improve AST (Aspartate Transaminase), ALT (Alanine Aminotransferase), GGT (Gamma Glutamyl Transpeptidase), TBiL (Total Bilirubin) and other biochemical indexes.

The invention discloses the application of Liuwei Anxiao pharmaceutical composition and its preparation in the preparation of drugs for treating alcoholic hepatitis. It is composed of six herbs such as seed and alkali flower. Clinical trials have shown that the Liuweian Xiaosan pharmaceutical composition has a protective effect on alcoholic liver injury, and can significantly improve biochemical indicators such as AST, ALT, GGT, and TBiL. <pb pnum="1" / >

The invention discloses a co-culture system for liver cells and Kupffer cells and application thereof. The co-culture system is characterized in that in a Millicell double-layer culture room, 1-100 ng / mL LPS (lipopolysaccharides) is added into a culture medium, the Kuffer cells are cultured in the upper layer of the Millicell double-layer culture room, and the liver cells are cultured in the lower layer of the Millicell double-layer culture room; and half of the fresh culture medium is replaced every other day so as to keep the concentration of the LPS. The co-culture system for liver cells and Kupffer cells provided by the invention has the advantages that the Kupffer cells continuously secrete inflammatory cell factors (such as TNF-alpha) in vitro after being stimulated by the LPS; the liver cells can generate a great number of enzymes, such as AST (aspartate aminotransferase), ALT (alanine transaminase) and GGT (gamma-glutamyl transpeptidase) in the environment so as to stimulate the liver injury based on immunoreaction caused by the immune / inflammation response after the liver tissue undergoes virus infection in vivo; and moreover, the co-culture system is used for screening medicaments resisting immune liver injury according to the influence of the medicaments on the secretion amount of immune factors and the enzymatic activity.

A method for producing Gamma-glutamyltranspeptidase by using Bacillus subtilis belongs to the biotechnology field of foods. The method carries out the three-stage culture of the slope, the seeds and the fermentation of the producing bacteria Bacillus subtilis SK11.004 of the Gamma-glutamyltranspeptidase; and the Gamma-glutamyltranspeptidase powder is obtained by carrying out separation and purification of fermentation broth. The provided method for producing the Gamma-glutamyltranspeptidase by using the Bacillus subtilis SK 11.004 has small breeding workload, low cost and safe and reliable performances, the method can carry out the liquid fermentation production, the cost is low, the method can be used in large-scale production, and the enzyme activity of the Gamma-glutamyltranspeptidase which is produced by using the Bacillus subtilis can be up to more than 4U / mL. The fermented product is non-toxic and can be directly used for producing a plurality of valuable Gamma-glutamyl compounds, such as L-Gamma-glutamyl-L-dopa, Gamma-glutamyl taurine, Gamma-glutamyl tryptophan, glutathione, theanine, and the like.